Physician profile
Allison A Overley
NPI 1437189461
$837.17
in general payments reported to CMS, 2019-2025
9 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $157 · 2023: $246 · 2024: $119 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $222.17 | 2023 | Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $149.61 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $119.83 | 2025 | Miebo, Xiidra |
| Aerie Pharmaceuticals, INC. | $111.41 | 2019 | |
| Abbvie INC. | $70.61 | 2024-2025 | |
| Astellas Pharma US INC | $56.95 | 2024 | Izervay |
| Ani Pharmaceuticals, INC. | $43.90 | 2025 | Yutiq, Purified Cortrophin Gel |
| Alimera Sciences, INC. | $43.29 | 2023-2024 | Iluvien, Yutiq |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Overley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.